We have recently reported a MET-independent early onset adaptive drug escape among the parental drug-sensitive EGFR-mutant lung adenocarcinoma cells (HCC827 and PC-9 to erlotinib; H1975 to CL-387,785)[13]. The gene discussed is EGFR; the disease is lung adenocarcinoma.